恩格列净保护小鼠抵抗饮食诱导的肥胖、胰岛素抵抗和肝脂肪变性
该研究在小鼠模型中测试恩格列净能否预防饮食诱导的肥胖和代谢紊乱。C57Bl/6小鼠接受西式饮食补充或不补充恩格列净10周,并以标准饮食对照。结果显示恩格列净补充预防了体重增加、胰岛素抵抗和肝脂肪变性,并改善骨骼肌线粒体形态,且不依赖于饮食类型。
要点
- 恩格列净补充预防了西式饮食诱导的小鼠体重增加、高血糖、高胰岛素血症和胰岛素抵抗。
- 恩格列净补充预防了西式饮食小鼠的肝脂肪变性,并改善肝脏胰岛素信号。
- 恩格列净补充增加了饮水量但不影响进食量,并使MRI测量的脂肪组织库显著减小。
核心结论
- 恩格列净在预防性设置下保护小鼠抵抗饮食诱导的体重增加、胰岛素抵抗和肝脂肪变性,并独立于饮食类型改善肌肉线粒体形态。
研究设计与样本
- C57Bl/6小鼠接受西式饮食补充恩格列净(WDE)或不补充(WD)10周,并以标准饮食不补充或补充恩格列净(CDE/CD)对照。
- 代谢表型分析包括体重、进食和饮水量、体成分、肝脏能量代谢、骨骼肌线粒体以及高胰岛素-正葡萄糖钳夹评估胰岛素敏感性。
主要发现
- WD喂养小鼠10周后超重、高血糖、高胰岛素血症且胰岛素抵抗,而WDE喂养小鼠预防了这些代谢改变。
- WDE喂养小鼠的饮水量显著增加,但WDE与WD喂养小鼠的进食量相似。
- MRI测量的脂肪组织库在WDE喂养小鼠中显著小于WD喂养小鼠。
- 恩格列净补充预防了WD喂养小鼠中出现的显著肝脂肪变性,且WD喂养小鼠肝脏胰岛素信号恶化而WDE喂养小鼠未恶化。
- 恩格列净补充对CD和WD喂养小鼠的骨骼肌线粒体大小和形态均有积极影响。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used in the treatment of type 2 diabetes, heart failure and chronic kidney disease. Their role in the prevention of diet-induced metabolic deteriorations, such as obesity, insulin resistance and fatty liver disease, has not been defined yet. In this study we set out to test whether empagliflozin prevents weight gain and metabolic dysfunction in a mouse model of diet-induced obesity and insulin resistance. METHODS: C57Bl/6 mice were fed a western-type diet supplemented with empagliflozin (WDE) or without empagliflozin (WD) for 10 weeks. A standard control diet (CD) without or with empagliflozin (CDE) was used to control for diet-specific effects. Metabolic phenotyping included assessment of body weight, food and water intake, body composition, hepatic energy metabolism, skeletal muscle mitochondria and measurement of insulin sensitivity using hyperinsulinaemic-euglycaemic clamps. RESULTS: Mice fed the WD were overweight, hyperglycaemic, hyperinsulinaemic and insulin resistant after 10 weeks. Supplementation of the WD with empagliflozin prevented these metabolic alterations. While water intake was significantly increased by empagliflozin supplementation, food intake was similar in WDE- and WD-fed mice. Adipose tissue depots measured by MRI were significantly smaller in WDE-fed mice than in WD-fed mice. Additionally, empagliflozin supplementation prevented significant steatosis found in WD-fed mice. Accordingly, hepatic insulin signalling was deteriorated in WD-fed mice but not in WDE-fed mice. Empagliflozin supplementation positively affected size and morphology of mitochondria in skeletal muscle in both CD- and WD-fed mice. CONCLUSIONS/INTERPRETATION: Empagliflozin protects mice from diet-induced weight gain, insulin resistance and hepatic steatosis in a preventative setting and improves muscle mitochondrial morphology independent of the type of diet.
引用
- Radlinger B, Ress C, Folie S, et al. Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis. Diabetologia. 2022. PMID: 36525084. doi:10.1007/s00125-022-05851-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。